EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nuclear DUX4 immunohistochemistry is a highly sensitive and specific marker for the presence of CIC :: DUX4 fusion in CIC ‐rearranged sarcomas : a study of 48 molecularly confirmed cases

Rodrigo T Macedo iD, Vira Baranovska-Andrigo, Tamás Pancsa iD, Natálie Klubíčková iD, Brian P Rubin, Scott E Kilpatrick, John R Goldblum, Karen J Fritchie iD, Steven D Billings iD, Michal Michal iD, Marián Švajdler, Zdeněk Kinkor und 2 weitere

Histopathology · 2025-02 · 86 (3) · 423-432

DOI: 10.1111/his.15341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, online erschienen am 09.10.2024. Verfasst von Rodrigo T Macedo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Diagnostic Institute, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Immunohistochemistry, Homeodomain Proteins, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education, Czech Republic (VB), Cooperatio Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

CIC ‐rearranged sarcomas (CRS) are clinically aggressive undifferentiated round cell sarcomas (URCS), commonly driven by CIC::DUX4 . Due to the repetitive nature of DUX4 and the variability of the fusion breakpoints, CIC::DUX4 fusion may be missed by molecular testing. Immunohistochemical (IHC) stains have been studied as surrogates for the CIC::DUX4 fusion. We aim to assess the performance of DUX4 IHC in the work‐up of CRS and its expression in non‐CRS round cell or epithelioid neoplasms. Methods and results Cases of molecularly confirmed CRS ( n = 48) and non‐CRS ( n = 105) were included. CRS cases consisted of 35 females and 13 males, with ages ranging from less than 1 year to 67 years (median = 41 years). Among the molecularly confirmed non‐CRS cases, C‐terminal DUX4 expression was investigated in Ewing sarcomas (38 cases), alveolar rhabdomyosarcomas (18 cases), desmoplastic small round cell tumours (12 cases) and synovial sarcomas ( n = five), as well as in non‐mesenchymal neoplasms such as SMARCA4/SMARCB1‐deficient tumours ( n = five), carcinomas of unknown primary ( n = three) and haematolymphoid neoplasms (four cases). DUX4 IHC was considered positive when strong nuclear expression was detected in more than 50% of neoplastic cells. When used as a surrogate for the diagnosis of CRS, the sensitivity and specificity of DUX4 IHC was 98 and 100%, respectively. Only one CRS case was negative for DUX4 IHC and harboured a CIC::FOXO4 fusion.

Conclusions

DUX4 IHC is a highly sensitive and specific surrogate marker for the presence of CIC::DUX4 fusion, demonstrating its utility in establishing a diagnosis of CRS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorImmunohistochemistryHomeodomain ProteinsOncogene Proteins, FusionSarcomaHumansFemaleMaleAdultMiddle AgedAgedAdolescentYoung AdultChildChild, PreschoolInfantSensitivity and SpecificitySoft Tissue NeoplasmsGene Rearrangement

Stichwörter der Autor:innen

CIC::DUX4CIC‐rearranged sarcomasimmunohistochemistryround cell sarcomasmall round cell tumours

Substanzen

Biomarkers, TumorHomeodomain ProteinsOncogene Proteins, FusionCIC-DUX4 fusion protein, humanDUX4L1 protein, human

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Diagnostic Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Pathology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
  • Biopticka laborator Ltd, Pilsen, Czech Republic.

ORCID-Profile: Rodrigo T Macedo, Tamás Pancsa, Natálie Klubíčková, Karen J Fritchie, Steven D Billings, Michal Michal, Josephine K Dermawan

Förderung

  • Ministry of Education, Czech Republic (VB)
  • Cooperatio Program

Zitieren

APA

Macedo, R. T., Baranovska-Andrigo, V., Pancsa, T., Klubíčková, N., Rubin, B. P., Kilpatrick, S. E., Goldblum, J. R., Fritchie, K. J., Billings, S. D., Michal, M., Švajdler, M., Kinkor, Z., Michal, M., & Dermawan, J. K. (2025). Nuclear DUX4 immunohistochemistry is a highly sensitive and specific marker for the presence of CIC :: DUX4 fusion in CIC ‐rearranged sarcomas : a study of 48 molecularly confirmed cases. Histopathology, 86(3), 423-432. https://doi.org/10.1111/his.15341

Vancouver

Macedo RT, Baranovska-Andrigo V, Pancsa T, Klubíčková N, Rubin BP, Kilpatrick SE, et al. Nuclear DUX4 immunohistochemistry is a highly sensitive and specific marker for the presence of CIC :: DUX4 fusion in CIC ‐rearranged sarcomas : a study of 48 molecularly confirmed cases. Histopathology. 2025;86(3):423-432. doi:10.1111/his.15341

BibTeX
@article{Macedo2025,
  author = {Macedo, Rodrigo T and Baranovska-Andrigo, Vira and Pancsa, Tamás and Klubíčková, Natálie and Rubin, Brian P and Kilpatrick, Scott E and Goldblum, John R and Fritchie, Karen J and Billings, Steven D and Michal, Michal and Švajdler, Marián and Kinkor, Zdeněk and Michal, Michael and Dermawan, Josephine K},
  title = {Nuclear DUX4 immunohistochemistry is a highly sensitive and specific marker for the presence of CIC :: DUX4 fusion in CIC ‐rearranged sarcomas : a study of 48 molecularly confirmed cases},
  journal = {Histopathology},
  year = {2025},
  volume = {86},
  number = {3},
  pages = {423--432},
  doi = {10.1111/his.15341}
}
Kostenlos starten →